---
format:
  revealjs:
    spotlight: true
    touch: true
    controls: true
    pointer: true
    center-title-slide: false
    transition: fade
    transition-speed: fast
    scrollable: true
    slide-number: true
    incremental: false
    multiplex: true
    chalkboard: true
    theme: [default, custom.scss]
    filters:
     - highlight-text
bibliography: references.bib
lightbox: true
csl: diagnostic-microbiology-and-infectious-disease.csl
revealjs-plugins:
  - pointer
filters:
  - highlight-text
---

## Principles of Antibiotic Therapy

<br> <br>

Russell E. Lewis <br> Associate Professor of Infectious Diseases <br> Department of Molecular Medicine <br> University of Padua

<br> {{< fa solid envelope size=1x >}} russelledward.lewis\@unipd.it <br> {{< fa brands github size=1x >}} https://github.com/Russlewisbo

![](University_of_Padua_seal.svg){fig-align="left" width="75"}

## Antibiotics- The Medical Miracle

![](resistance.jpg){fig-align="center"}

## Mortality reduction with antibiotic therapy {.smaller}

<br>

<br>

+------------------------------+--------------------+----------------+--------------+
| Disease                      | Pre-antibiotic era | Antibiotic era | Change       |
+==============================+====================+================+==============+
| Community-acquired pneumonia | \~ 35%             | \~ 10%         | -25%         |
+------------------------------+--------------------+----------------+--------------+
| Nosocomial pneumonia         | \~ 60%             | \~ 30%         | -30%         |
+------------------------------+--------------------+----------------+--------------+
| Bacterial endocarditis       | \~ 100%            | \~ 25%         | -75%         |
+------------------------------+--------------------+----------------+--------------+
| Gram-negative bacteremia     | \~ 70%             | \~ 10%         | -60%         |
+------------------------------+--------------------+----------------+--------------+
| Bacterial meningitis         | \> 80%             | \< 20%         | -60%         |
+------------------------------+--------------------+----------------+--------------+
| Skin infection o             | \~ 11%             | \< 0.5%        | -10%         |
+------------------------------+--------------------+----------------+--------------+

<br>

::: footer
[@spellberg2025]
:::

## Antibiotics: <br> Essential for practice of modern medicine {background-image="images/antibiotic-resistance.jpg" background-opacity="0.3"}

<br>

-   Enable complicated and deeply-invasive surgery

-   Aggressive chemotherapy for cancer

-   Fundamental aspects of critical care

    -   e.g., central venous catheters, mechanical ventilation

-   Care for premature infants, mothers (post-partum sepsis)

-   Solid organ and stem cell transplantation

-   **Antibiotics created a revolution in the practice of medicine, transforming a primarily diagnostic-focused field to a *therapeutic, interventional* profession**

::: footer
[@spellberg2025]
:::

## Current antibiotic resistance statistics

<iframe src="https://vizhub.healthdata.org/microbe/?settings=eyIxIjoia2V5X2ZpbmRpbmdzIiwiMiI6ImJhciIsIjMiOiJhbXIiLCI0IjoyMiwiNSI6MSwiNiI6MywiNyI6MywiOCI6MSwiOSI6MSwiMTIiOjMsIjEzIjoxLCIxNCI6MSwiMTUiOjEsIjE2IjoxLCIxNyI6MywiMTgiOjIwMjEsIjE5IjpmYWxzZSwiMjAiOmZhbHNlLCIyMiI6MSwiMjQiOiJlbiIsIjI1Ijoic3luZHJvbWUiLCIyNiI6WzEsMiwzLDQsNSw2LDcsOCw5LDEwLDIyXSwiMjciOls0LDMxLDY0LDEwMywxMzcsMTU4LDE2Nl0sIjI4IjpbMiwzLDQsNSw2LDcsOCw5LDEwLDExLDEyLDEzXSwiMjkiOlsxLDJdLCIzMCI6WzEsNywxMSwxNywyMywyMl0sIjMxIjpbIjEtMSIsIjEtMiJdLCIzMiI6IjEtMSIsIjMzIjpbMSwyXX0=" width="100%" height="900px">

</iframe>

::: footer
Source: healthdata.org
:::

## World Health Organization (WHO) <br> Pathogen Priority List

![](images/WHO.png){fig-align="center" width="600"}

## Methicillin-resistant <br> *Staphylococcus aureus* (MRSA)

<br>

![](images/MRSA_ITALY.png){fig-align="center"}

## Carbapenem-resistant Enterobacterales (CRE)

<br>

![](images/CRE_ITALY.png){fig-align="center"}

## Multi-drug resistant (MDR) <br>*Acinetobacter baumannii*

<br>

![](images/MDRABUAM_ITALY.png){fig-align="center"}

## Antibiotic discovery is slowing

<br>

<br>

![](images/discovery.png){fig-align="center"}

## Antibiotics are a societal trust

<br> <br>

-   Antibiotic overprescription is a ***tragedy of the commons***: individual undertakes an action that they perceive to be in their own self-interest but that causes harm to society at large

-   When such an action is undertaken rarely, the harm to society is not noticeable

-   When it happens tens of millions of times per year, as with inappropriate antibiotic prescriptions, **the collective harm to society can be catastrophic**

-   Given the power of antibiotics to save lives, and the constant erosion of that power through their use, **one of the most important functions of the physician is to serve as an expert *in the use and protection of antimicrobial agents***

## Antibiotic stewardship

<br>

+---------------------------------------+---------------------------------------+
| ![](images/steward1.png){width="800"} | ![](images/steward.jpeg){width="800"} |
+---------------------------------------+---------------------------------------+

## 10 Principles for effective use of <br> antibacterial therapy {.smaller}

<br>

::: nonincremental
1.  Accurate differential diagnosis

2.  Only use antibiotics when they alter the clinical course

3.  Empirically target microbes in differential diagnosis

4.  A lower threshold for empirical therapy should be used in critically-ill patients

5.  Host factors affect the spectrum of empirical therapy

6.  PK/PD principles impact optimal treatment

7.  De-escalate antibiotic therapy based on microbiology results and clinical (biomarker) responses

8.  If therapy is not working, consider source control or alternative diagnosis before broadening therapy

9.  Distiniguish new infection from failure of initial therapy

10. The duration of therapy should be as short as possible based on available evidence (shorter is better)
:::

## Principle #1: Accurate differential diagnosis

<br>

<br>

### What is the most tool for deciding to start antibiotic therapy?

<br>

A. Patient medical history

B. Physical exam

C. Radiological imaging (e.g., X-ray, CT or MRI)

D. Microbiological tests (e.g., culture, PCR, biomarkers, serology)

## Medical history in infectious diseases {.smaller}

<br>

-   **What are the current symptoms** (e.g., fever, pain, cough, breathlessness, confusion, lethargy, vomiting, and any acute or subacute changes in functional status such as new urinary incontinence, falls, or decreased oral intake)

    -   **8 cardinal descriptors**: Timing, Location, Character, Aggravating Factors, Alleviating Factors, Associated Symptoms, Severity, Setting

-   **Fever** How high, how long, what pattern?

-   **Risk factors for infection** (e.g., indwelling devices -urinary catheters, vascular catheters, prosthetic joints, cardiac devices), recent medical procedures, immunosuppression, diabetes, history of injection drug use, and previous infections

-   **Travel or exposure history** (e.g., recent travel (countries, regions, urban/rural, dates), exposure to animals or insect bites, contact with ill individuals, and consumption of potentially contaminated food or water)

-   **Sexual history** and risk for sexually transmitted infections

-   **Vaccination history**

-   **What is the past medical and surgical history, medication use, and allergies?**

-   **Are there any recent changes in medications or antibiotic use?**

-   **What is the social history?** (e.g., living situation (e.g., long-term care facility), occupation, hobbies, and substance use, which may affect exposure risk)

## Case Example

::::: columns
::: {.column width="50%"}
-   **Chief complaint:** 34 year-old farmer from Sicily presents with worsening back pain after sitting for more than couple of hours

-   **No other significant past medical history**

-   **Spondylitis etiologies:**

    -   \> 50% *Staphylococcus aureus, Staphylococcus epidermidis*

    -   \~ 25% *Streptococcus* spp., *Enterococcus* spp. *Pseudomonas aeruginosa,* *Enterobacter* spp., *Proteus* spp. *E. coli*, *Serratia* spp., Anaerobes, *Mycobacterium tuberculosis* (Pott’s disease)
:::

::: {.column width="50%"}
![Initial lateral radiograph (left) shows a cortical disruption at the inferior epiphyseal plate of L4 vertebral body (arrows). The sagittal fat suppressed contrast enhanced T1-w MR image (right) shows septic discitis (open arrow) and bone marrow edema on both L4 and L5 vertebral bodies (arrows), suggesting spondylitis.](images/spondylitis.png){fig-align="center"}
:::
:::::

## Pertinent history!

<br>

-   Patient works as a sheep and cattle farmer in a small enterprise 54 minutes from Messina that produces milk and cheese: Percorino salato and Ricotta

-   Patient reported pain was first noticed at end of May after a bad case of flu “fever, achy joints, headache”

-   Father (who also works on farm) also has worsening hip pain after sitting for long periods and will be evaluated by an orthopedic doctor for hip replacement.

-   Other 3 brothers and cousin who work on farm report no illness.

## Could this be brucellosis?

<br>

![](images/brucellosis.png){fig-align="center"}

::: footer
[@massis2005]
:::

## Diagnosis and treatment of <br>Brucellosis spondylitis

<br>

-   Blood cultures require special procedures (prolonged incubation), bone culture may be needed

-   Brucella PCR from clinical specimen

-   Combination serologic studies

-   Treatment- Gentamicin + Doxycycline + Rifampin

    -   Unconventional antibiotic regimen, would not be covered by standard spondylitis regimens

## Antibiotics are usually started empirically

```{dot}
digraph infection_timeline {
    // Graph settings
    rankdir=TB;
    splines=ortho;
    nodesep=0.6;
    ranksep=0.8;
    bgcolor="white";
    
    // Node defaults
    node [
        shape=box,
        style="filled,rounded",
        fillcolor="#F5DDD1",
        color="#F5DDD1",
        fontname="Arial",
        fontsize=14,
        width=3,
        height=0.6
    ];
    
    // Edge defaults
    edge [
        color="#D4764A",
        arrowsize=0.8,
        penwidth=1.5
    ];
    
    // Time labels (invisible nodes for positioning)
    node [shape=plaintext, fillcolor=transparent, color=transparent, fontcolor="#333333", fontsize=18];
    t0 [label="0h"];
    t1 [label="1h"];
    t24 [label="24h"];
    t48 [label="36-48h"];
    t72 [label="72-96h"];
    
    // Annotation labels - 200% larger (fontsize=24)
    node [fontsize=24, fontcolor="#333333"];
    empiric [label=<Begin <b>empiric therapy </b> for<br/>likely pathogens>];
    definitive [label=<Change to <b>definitive therapy</b><br/>for patient-specific pathogens>];
    
    // Main process nodes
    node [shape=box, style="filled,rounded", fillcolor="#F5DDD1", color="#F5DDD1", fontcolor="black", fontsize=14];
    suspect [label="Suspect infection"];
    culture [label="Culture suspected sites"];
    gram [label="Gram stain"];
    id [label="Identification"];
    suscept [label="Susceptibilities"];
    
    // Main flow
    suspect -> culture -> gram -> id -> suscept;
    
    // Position time labels and annotations using same rank
    {rank=same; suspect; t0}
    {rank=same; culture; t1; empiric}
    {rank=same; gram; t24}
    {rank=same; id; t48}
    {rank=same; suscept; t72; definitive}
    
    // Invisible edges for positioning
    edge [style=invis];
    empiric -> culture;
    culture -> t1;
    suspect -> t0;
    gram -> t24;
    id -> t48;
    suscept -> t72;
    t72 -> definitive;
}
```

## Antibiotics are usually started empirically {.smaller}

Antibiotics should only be started if the differential diagnosis includes likely invasive bacterial infections: <br>**90-98% of upper respiratory tract infections are caused by viruses**

![](images/URI.png){fig-align="center"}

Clinicians frequently *overestimate* the risk of bacterial infection

::: footer
[@chow2012]
:::

## But Clinicians frequently *underestimate* the risks of antibiotic therapy

<br>

<br>

::: callout-warning
## 1 in 5 patients given antibiotic prescriptions are harmed by them because of adverse events or superinfection by resistant pathogens or *Clostridioides difficile*
:::

<br>

::: callout-warning
## Every additional 10 days of antibiotic therapy confers a 3% increased risk of an adverse drug effect
:::

<br>

A combination of:

-   Fear from uncertainty of the diagnosis

-   Lack of appreciation of how dangerous antibiotics can be

::: footer
[@tamma2017b]
:::

## Association of adverse events with antibiotic use in hospitalized patients

![](images/adverseeffects.png){fig-align="center"}

::: footer
[@tamma2017b]
:::

## Positive cultures <br>are not always proof of infection {.smaller}

<br>

-   The presence of a positive culture in the absence of signs or symptoms of infection **should not** reflexively trigger antibiotic prescription.

-   IN the abscence of signs or symptoms of infection, a positive culture often represents **colonization or contamination** and should not trigger treatment. <br> <br>

+-----------------------+-----------------------+---------------------------+------------------------------+-----------------------+
| Wound swabs           | Urine cultures        | Bronchial alveolar lavage | Respiratory samples          | GI tract/stool        |
+=======================+=======================+===========================+==============================+=======================+
| ![](images/wound.png) | ![](images/urine.png) | ![](images/BAL.png)       | ![](images/nasal%20swab.png) | ![](images/stool.png) |
+-----------------------+-----------------------+---------------------------+------------------------------+-----------------------+

## Simple stewardship interventions

![](images/computer.png){fig-align="center"}

::: footer
[@luu2021]
:::

## Simple stewardship intervention- a big impact!\|

![](images/outcomes.png){fig-align="center"}

::: footer
[@luu2021]
:::

## Principle #2: Only use antibiotics when they alter the clinical course of patients

-   The administration of antibiotics should not be a reflexive response to infection, but should be incorporated into an overall, rational therapeutic plan for the patient.

-   Patients who lack bacterial infections cannot have their clinical course improved by antibiotics (as discussed in Principle #1).

    ![Chronic osteomyelitis with exposed bone](images/osteo.png){fig-align="center"}

## Ethical dilemmas for use of antimicrobial therapy

<br>

| End of life (comfort care) | Non-adherent HIV therapy |
|----------------------------|--------------------------|
| ![](images/terminal.png)   | ![](images/HIV.png)      |

## Principle #3: Empirically target microbes in differential diagnosis

## Know the spectrum of activity

+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+
| -   Spectrum of activity of the empirical antiinfective agents prescribed should be tailored to cover the likely microbial flora that cause the diseases in the differential diagnosis | ![](images/Sanford.png)                        |
|                                                                                                                                                                                        |                                                |
|                                                                                                                                                                                        | [Sanford Guide](https://web.sanfordguide.com/) |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+

## Community-acquired vs. nosocomial

![](images/respiratory.png){fig-align="center"}

## Basic principles of coverage {.smaller}

<br> <br>

+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------+
| Community infections                                                                                                                                                                     | Nosocomial infections                                                                                                                     |
+==========================================================================================================================================================================================+===========================================================================================================================================+
| -   Community-associated infections are infrequently caused by MDR gram-negative bacteria.                                                                                               | More often caused by more resistant pathogens, and hence require coverage for P*seudomonas* or other non-fermenting gram-negative bacilli |
|                                                                                                                                                                                          |                                                                                                                                           |
| -   Empirical antibiotic coverage should not routinely considered                                                                                                                        |                                                                                                                                           |
+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------+
| Avoid using routine methicillin-resistant *S. aureus* (MRSA) empirical therapy in patients who are unlikely to be infected with MRSA                                                     | Greater risk for MRSA, especially is patient has recently received antibiotic therapy                                                     |
+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------+
| Reserve the use of antimicrobials that can be used as last-line oral therapeutic options (e.g., fluoroquinolones) for infections for which there are no reasonable alternative therapies | May require "frontline" used of lastline antibiotic if patient has risk factors for multidrug resistant infection                         |
+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------+

<br> Special circumstances creates exceptions: For example, community-acquired pneumonia and intraabdominal, skin, and urinary infections may be caused by *Pseudomonas* in patients with cystic fibrosis or with history of bronchiectasis, chronic dialysis patient, or patient with indwelling catheters or recent surgery.

## Principle #4: There is a lower threshold for empirical therapy in critically-ill patients

![](images/ICU.png){fig-align="center" width="600"}

## Antibiotic timing is critical in septic shock

![](images/kumar.png){fig-align="center"}

::: footer
[@kumar2006]
:::

## Principle #5: Host factors affect the spectrum of empirical therapy

![](images/immunocompromise.png){fig-align="center"}

## Common immunocompromised conditions

+-------------------------+-------------------------------------------------------------------------------------+
| ![](images/patient.png) | 1.  Chronic diseases (e.g., type 1 diabetes, chronic obstructive pulmonary disease) |
|                         |                                                                                     |
|                         | 2.  Autoimmune diseases (e.g., lupus, rheumatoid arthritis)                         |
|                         |                                                                                     |
|                         | 3.  Genetic diseases (primary immunodeficiencies)                                   |
|                         |                                                                                     |
|                         | 4.  Cancer and/or chemotherapy                                                      |
|                         |                                                                                     |
|                         | 5.  Human immunodeficiency virus (HIV)                                              |
|                         |                                                                                     |
|                         | 6.  Solid organ or bone marrow transplant                                           |
|                         |                                                                                     |
|                         | 7.  Advanced age                                                                    |
|                         |                                                                                     |
|                         | 8.  Malnutrition                                                                    |
|                         |                                                                                     |
|                         | 9.  **Chronic use of corticosteroids or other immunosuppressive medications**       |
|                         |                                                                                     |
|                         | 10. Chronic infections                                                              |
|                         |                                                                                     |
|                         | 11. Smoking                                                                         |
+-------------------------+-------------------------------------------------------------------------------------+

## Glucocorticoids: <br>"Credit cards" of immunosuppressive therapy

![](images/glucocorticoids.png){fig-align="center" width="400"}

Dose-dependent increase in the risk of opportunistic infections \> 10 mg of prednisone equivalents (PEQ) per day for 2-4 weeks

::: aside
<br>

<br>

<br>

[@chastain2023]
:::

## Community acquired pneumonia (CAP) vs. <br> Pneumocystis jirovecii pneumonia (PCP)

+---------------------------------------+------------------------------------------+
| ![](images/PCP_xray.png){width="449"} | ![](images/PCP_CT.png){width="427"}      |
|                                       |                                          |
| Diffuse bilateral infiltrates         | Patchy areas of ground-glass attenuation |
+---------------------------------------+------------------------------------------+

## Principle #6: PK/PD principles impact optimal treatment

```{dot}
digraph G {
	fontname="Lato,Arial,sans-serif"
	node [fontname="Lato,Arial,sans-serif"]
	edge [fontname="Lato,Arial,sans-serif"]


patient -> PK;
drug -> PK;
intrinsic-> PD;
acquired -> PD;
inoculum -> PD;
PK -> PKPD;
PD -> PKPD;
PKPD -> microbiological;
microbiological -> clinical;

  clinical [shape=box, label="Clinical outcome"];
  microbiological [shape=box, label="Microbiological outcome"];
  PK [shape=oval, label="Pharmacokinetics (PK)"];
  PD [shape=oval, label="Pharmacodynamics (PD)"];
  PKPD [shape=oval, label="PK/PD"];
  patient [shape=none, label="Patient factors"];
  drug [shape=none, label="Drug factors"];
  intrinsic [shape=none, label="Intrinsic resistance"];
  acquired [shape=none, label="Acquired resistance"];
  inoculum [shape=none, label="Infection inoculum"];
}
```

::: aside
[@theuretzbacher2012]
:::

## Pharmacology of antimicrobials

```{dot}
digraph G {
 	rankdir=LR
 	fontname="Lato,Arial,sans-serif"
	node [fontname="Lato,Arial,sans-serif"]
	edge [fontname="Lato,Arial,sans-serif"]
 
  subgraph cluster_0 {
    style=filled;
    color=lightblue;
    node [style=filled,color=white];
    start -> dosing;
    dosing -> tissue;
    dosing -> infection;
    label = "Pharmacokinetics (PK)";
    graph [labelloc=a]
    
    
    
  }
  
    subgraph cluster_1 {
    line=black;
    style=filled;
    color=lightblue;
    node [style=filled,color=white];
  tissue->PD1
    infection-> PD2;
    label = "Pharmacodynamics (PD)";
  }
  
 
  start [shape=Box, label="Dosing regimen"];
  dosing [shape=rectangle, style=filled,color=yellow, label="Conc. vs. \n time in serum", xlabel=" \n    \n  \nAbsorption \nDistribution \nMetabolism \nElimination"];
  tissue [shape=rectangle, style=filled,color=white, label="Conc. vs. \n time in tissue"];
  infection [shape=rectangle, style=filled, color=white, label="Conc. vs. \n time at site of \n infection"];
  PD1 [shape=rectangle, label="Pharmacological or  \n toxicological effect"]; 
  PD2 [shape=rectangle, label="Antimicrobal effect \n vs. time"];
}


```

::: aside
[@craig_1998]
:::

## Key pharmacokinetic variables

<br>

![](images/AUC.png){fig-align="center"}

## Key pharmacokinetic variable: <br>Volume of distribution (Vd)

<br>

-   The volume which appears to hold the drug if it was present in the body at the same concentration found in plasma

    -   It is estimated, not directly measured

-   Reported in liters (L) or liters per kilogram (L/kg)

-   Average plasma volume in adults is approximately 3 L

## Key pharmacokinetic variable: <br>Volume of distribution (Vd)

![](images/vd_breakdown.png){fig-align="center" width="400"}

## Volume of distribution

<br>

<br>

::::: columns
::: {.column width="50%"}
![](images/Vd.png){width="600"}
:::

::: {.column width="50%"}
-   Plasma volume= 3L+ Extracellular water 16 L = Total body water (\~20L)

-   Higher Vd (e.g., \> 46 L Vd)= sequestered in depot (e.g., fat) and serum concentrations will be lower
:::
:::::

## Volume of distribution (Vd): <br> relevance for antibiotic selection

![](images/vd_clinical%20relevance.png){fig-align="center"}

## Vd alterations

![](images/clipboard-943880396.png){fig-align="center"}

## Vd changes in critical illness

![](images/clipboard-20417349.png)

## Drug penetration in ventilator-associated pneumonia

![](images/clipboard-1264925385.png)

## Anatomically-privileged sites

![](images/clipboard-1377245329.png)

## Anatomically-privileged sites

![](images/clipboard-1890359177.png){width="800"}

## Match the antibiotic to site of infection

![](images/clipboard-1230498658.png)

## Urinary concentrations of antibiotics

![](images/clipboard-2574271174.png)

## PK/PD indices

![](images/clipboard-2657724390.png)

## How are PK/PD indicies identified?

![](images/clipboard-2182940819.png)

## Do PK/PD indices correlate with <br> clinical outcome of antibiotic therapy

![](images/clipboard-406664738.png)

## PK/PD characteristics of common antibiotic classes

![](images/clipboard-3004890051.png)

## Application: Optimized dosing of meropenem

<iframe src="https://tdmx.shinyapps.io/Meropenem/" width="100%" height="900px">

</iframe>

<https://www.tdmx.eu/Launch-TDMx/>

## Daptomycin is inactivated in the lung

![](images/clipboard-3779354213.png)

## Antibiotic activity in abscess

<br>**Aminoglycosides**

::::: columns
::: {.column width="50%"}
-   Bind and are inactivated by purulent material

-   Decrease aminoglycoside uptake into facultative aerobic bacteria at low pH

-   **Penicillins and tetracyclines**

    -   Bound by hemoglobin, less effective with hematoma formation

    -   Emphasizes importance of source control (abscess drainage, removal of prosthetic material)
:::

::: {.column width="50%"}
![](images/clipboard-3855805086.png)
:::
:::::

## Principle #7: De-escalate antibiotic therapy based on microbiology results and clinical (biomarker) responses

<br>

![](images/microbiological%20workup.png){fig-align="center"}

## Antibiotic de-escalation

<br>

-   De-escalation with pathogen identification

    -   -e.g., stopping empirical vancomycin in patient with Gram-negative bacilli in blood cultures

-   Clinical improvement-reduction in fever and leukocytosis

-   Empiric de-escalation of therapies for highly-resistant pathogens if they have not grown from culture

    -   e.g., stopping empirical vancomycin in a patient without positive MRSA cultures

-   Biomarkers: C-reactive protein (clinical utility questioned), procalcitonin -*areas of diagnostic stewardship as tests are frequently abused*

::: notes
Clinicians often ignore negative results but may use a positive procalcitonin to justify antibiotic use
:::

## Incorporation of procalcitonin into therapeutic decisions reduces antibiotic use<br>

::: footer
[@schuetzProcalcitoninGuideInitiation2012]
:::

## Choosing therapy : <br> gram-stain vs. guidelines

![](images/grace_trial.png){fig-align="center" width="1200"}

-   Gram strain guided therapy resulted in a 30% reduction in use of anti-pseudomonal agents and 40% reduction in MRSA agents

-   Gram-stain guided therapy resulted in higher rate of appropriate antibiotic escalation (7% vs. 1%, p=0.03)

::: footer
[@yoshimura2022]
:::

## Susceptibility testing

![](images/MIC.png){fig-align="center"}

## Principle #8: If therapy is not working, consider source control or alternative diagnosis before assuming resistance and broadening therapy

-   Treatment decisions may need If an antibiotic therapy has not improved:

    -   Fever curve
    -   White blood cell count
    -   Purulent secretions
    -   Signs of inflammation (*rubor, tumor, dolor, calor)*
    -   Biomarkers (procalcitonin)

## Source control {.smaller}

<br> <br>

+-------------------------------------------+---------------------------------------------------+-----------------------------------------+---------------------------------------------------------+---------------------------------------------+
| Occult subcutaneous abscess in cellulitus | New abscess formation in intraabdominal infection | Empyema in community-acquired pneumonia | Visceral or skeletal abscess in patient with bacteremia | Failure to remove a central venous catheter |
+-------------------------------------------+---------------------------------------------------+-----------------------------------------+---------------------------------------------------------+---------------------------------------------+
| ![](images/abscess.png)                   | ![](images/abdominlaabscess.png)                  | ![](images/empyema.png)                 | ![](images/spondylitis.png)                             | ![](images/biofilm.png)                     |
+-------------------------------------------+---------------------------------------------------+-----------------------------------------+---------------------------------------------------------+---------------------------------------------+

## Antibiotic FAIL

-   **F**alse diagnosis

-   **A**llergies

-   **I**ntercurrent infections

-   **L**ocalized process

\##

## Principle #9: Distinguish new infection from failure of initial therapy

<br>

-   New onset of infectious signs, symptoms, and biomarkers after resolution of prior infection should raise the concern of a new infection rather than persistence of the original infection

-   Rarely, recrudescence of signs and symptoms may reflect emergence of antibiotic resistance on therapy from the initial pathogens

    -   This may be seen more with specific bacterial pathogens, such as *Acinetobacter baumannii*, than with others.

    -   An initial apparent response to infection followed days or weeks later by new onset of infectious signs or symptoms should prompt a complete reevaluation of the patient for a new infection, including reculturing and imaging if necessary.

-    In these patients, it is generally reasonable to broaden therapy to cover highly resistant pathogens.ù

    -   Such patients have been exposed to recent courses of antibiotics and have a higher risk of being infected by antibiotic-resistant pathogens.

-   When changing antibacterial therapies because of breakthrough infection or lack of response to initial therapy, it is generally advisable to change one antibiotic at a time (to a different class if possible)

## Principle #10: The duration of therapy should be as short as possible based on available evidence (shorter is better)

<br>

| Disease | Short course (days) | Long course (days) | Outcome |
|----|----|----|----|
| Bacteremia, gram-negative | 7 | 14 | Equivalent |
| Chronic bronchitis and COPD | ≤ 5 days | ≥ 7 | Equivalent |
| Intra-abdominal infection | 4 | 10 | Equivalent |
| Neutropenic fever | Until afebrile and stable | Until, afebrile, stable and non-neutropenic | Equivalent |
| Osteomyelitis, chronic | 42 | 84 | Equivalent |
| Pneumonia, community-acquired | 3-5 | 7-10 | Equivalent |
| Pneumonia, nosocomial (including VAP) | ≤ 8 | 10-15 | Equivalent |
| Pyelonephritis | 5-7 | 10-14 | Equivalent |
| Skin infections (cellulitis, major abscess, wound infections) | 5-6 | 10-14 | Equivalent |
| Sinusitis, acute bacterial | 5 | 10 | Equivalent |

::: fotter
[@spellbergPrinciplesAntibioticTherapy2025]
:::

## Common myths of antibiotic therapy

## Bactericidal antibiotics are more effective than bacteriostatic

## Oral therapy is less effective than IV <br> for complex infections

## Combination therapy: *The good, the bad,...the ugly*

## Does combination therapy prevent resistance?

## References
